HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Hematology
Meta-analysis
Reduced-intensity ATRA plus arsenic with GO or low-dose anthracycline improves event-free survival in high-risk APL
New analysis shows reduced-intensity treatment works well for high-risk leukemia patients compared to standard intensive chemotherapy
This systematic review and meta-analysis of 1,323 patients with high-risk acute promyelocytic leukemia found that reduced-intensity inductio…
A large review of over 1,300 patients found that a gentler treatment plan worked just as well as harsher chemotherapy. This approach may hel…
Frontiers
May 29, 2026
Orthopedics & Sports Medicine
Meta-analysis
Case report and review of TTMV::RARA-positive APL with spinal cord compression in a child
Doctors treated a boy with rare leukemia and spinal pressure using special drugs
This is a case report with a systematic review of 11 published cases of TTMV::RARA-positive acute promyelocytic leukemia (APL). The authors …
A nine-year-old boy had rare leukemia and spinal cord pressure. Doctors used specific drugs that helped clear the disease and fix his spine.
Frontiers
May 9, 2026
Oncology
Sys. Review
Review of ATRA and ATO induction therapy in acute promyelocytic leukemia with RNA sequencing insights
Why PCR Missed This Leukemia
This case report and literature review examines induction therapy using all-trans retinoic acid and arsenic trioxide in acute promyelocytic …
A standard blood test missed a dangerous leukemia because the disease had a unique genetic pattern that routine screening overlooked until a…
Frontiers
Apr 16, 2026
Oncology
Sys. Review
Case report of ATRA and VAH regimen in refractory EVI1-positive AML
New hope for tough AML cases
This case report with a brief literature review describes a 42-year-old patient with refractory EVI1-positive AML.
A patient with high-risk AML and the tough EVI1 marker achieved complete remission after failing standard treatments, offering new hope for …
Frontiers
Apr 16, 2026